Last updated on August 2019

Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic renal failure | chronic renal insufficiency | Non Valvular Atrial Fibrillation
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • male and female patients, age 18 years
  • CKD with eGFR 15 - 49 mL/min per 1.73 m2
  • non-valvular atrial fibrillation (NVAF) with indication for anticoagulation therapy
  • a treatment strategy for the 3 previous months before enrolment with either: rivaroxaban or VKA (OAC cohorts) or no anticoagulation (no AC cohort)
  • informed consent
  • availability for follow up
  • life expectancy of 6 months

Exclusion Criteria:

  • exclusion criteria according to the local product information for the respective anticoagulation treatment
  • planned treatment with other anticoagulants
  • expected renal-replacement therapy within the next 3 months

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.